MORF News and Press, Morphic Holding Inc. From 03/02/21

After more than doubling on Monday, Morphic Holding 's (NASDAQ: MORF) shares are taking a beating on Tuesday. As of 11:10 a.m. EST, the biopharmaceutical company's stock is down by 13.6%. There are two likely explanations for Morphic Holding's losses on the stock market today. First...

Gainers: NanoViricides NNVC +63%, CHF Solutions CHFS +25%, Avenue Therapeutics (ATXI) +19%, Fortress Biotech FBIO +17%, STRATA Skin Sciences (SSKN) +15%.Losers: FibroGen FGEN -30%, Neuronetics STIM -14%, RedHill Biopharma RDHL&#...

FibroGen (FGEN) -25% on Q4 earnings release and after FDA to hold AdCom meet to review FibroGen, AstraZeneca's kidney drug.Comstock Mining (LODE) -19% after launching 4M-share public offering.Inseego (INSG) -16% on Q4 earnings release.RedHill Biopharma (RDHL) ...

BMO Capital Markets becomes the latest firm to have a favorable view on Morphic Holding (MORF) after the company’s pre-market announcement of positive interim data for MORF-057 in inflammatory bowel disease.With an overweight rating, the analyst raised the price target to $111.00 ...

Morphic Holding (MORF) announces a proposed underwritten public offering in which it intends to offer and sell $200M of shares.The company intends to grant the underwriters a 30-day option to purchase up to an additional $30M of shares.Morphic intends to use the net proceeds from the proposed...

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it inte...

Should Investors Have These Top Health Care Stocks On Their Watchlist? Health care stocks are one of the biggest winners to come out of this pandemic. It is one of the best sectors to invest in right now. The health care industry is one of the most complex and largest sectors in...

Morphic Holding, Inc. (MORF) Q4 2020 Earnings Conference Call March 1, 2021 8:00 A.M. ET Company Participants Chris Erdman - Senior Vice President of Communications Praveen Tipirneni - Chief Executive Officer Marc Schegerin - Chief Operating Officer and Chief Financial Officer Bruce Rogers - ...

Following the announcement of positive Phase 1 interim results for MORF-057 in inflammatory bowel disease, Wells Fargo has more than doubled the price target of Morphic ([[MORF]] +132.3%) to $103.00 from $40.00 per share, a ~184.8% upside to the previous close.The analyst Yanan Zhu ...

Shares of Morphic Holding (NASDAQ: MORF) are soaring through the roof on Monday, following the company's release of its fourth-quarter and full-year 2020 earnings report. More important than its financial results, the biopharmaceutical company announced results from a clinical trial...